The Role of Vaccines in the Prevention of HPV Cervical Cancer in Iran between (2018 -2020)

Faegheh Miryousefiata, Sareh Sangy


ervical cancer is one of the leading causes of death in women of childbearing age in developing countries Are related. The HPV study is the fourth most malignant disease in women in the world. 15% of cervical cancers with the virus and cervical cancer was performed. The present HPV aims to investigate the role of vaccines in the prevention of infection. This study reviews information between 2018 and 2020 in Iran by searching databases. The most common sexually transmitted infection is self-limiting. HPV in men and women. HPV vaccination, which is associated with the development of oral-anal cancers, including cervical cancer and genital warts, HPV infection prevents. Vaccination Gardasil vaccine can provide up to 11% protection against cervical cancer The new nine are up to 19% effective against highly malignant cancers of the cervix and even the vagina. Increase day ads and ways of transmission and pathogenesis and treatment of vaccination of this virus leads to improved control of HPV over the prevalence Disease and ultimately controlling the consequences of the virus as well as the possibility of eradicating cervical cancer in decades The future will be.


incidence; prevention; cervical malignancy; papilloma virus vaccine; papilloma virus

Full Text:



Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63(RR-05):1-30.

Bzhalava D. Human papillomavirus reference clones. International Human Papillomavirus Reference Center. Available at: URL:, consulté en septembre; 2014.

Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(Suppl 5):F55-70.

Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3):S3/35–41.

Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89(43):465- 91.

Safaei A, Khanlari M, Momtahen M, Monabati A, Robati M, Amooei S, et al. Prevalence of high-risk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran. Indian J Pathol Microbiol 2010; 53(4):681-5.

Shahramian I, Heidari Z, Mahmoudzadeh-Sagheb H, Moradi A, Forghani F. Prevalence of HPV infection and high risk HPV genotypes (16, 18), among monogamous and polygamous women, in Zabol, Iran. Iran J Public Health 2011; 40(3):113–21.

Miryousefiata F, Alsadat Miryousefiata F. The effect of Familact probiotic supplement in patients with diabetes (Evaluation of Blood Glucose Parameters, Lipid Profile). Academic Journal of Health Sciences. 2021; 36 (3): 52-63. doi: 10.3306/AJHS.2021.36.03.52

Sohrabi A, Farzami MR, Samiee SM, Modarresi MH. An overview on papillomaviruses as the main cause of cervical cancer. Iran J Obstet Gynecol Infertil 2015; 18(145):14-25. (Persian).

Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105(1):28-37.

Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121(3):621–32.

Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R, et al. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrol Dial Transplant 1994; 9(4):416–20.

Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 30(Suppl 5):F168–74.

WHO Guidelines Approved by the Guidelines Review Committee. WHO guidelines for screening and treatment of precancerous lesions for cervical Cancer prevention. Geneva: World Health Organization; 2013.

WHO Guidelines Approved by the Guidelines Review Committee. WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Geneva: World Health Organization; 2011.

Khatibi M, Rasekh HR, Shahverdi Z, Jamshidi HR. Cost-effectiveness evaluation of quadrivalent humanpapilloma virus vaccine for HPV-related disease in Iran. Iran J Pharm Res 2014; 13(Suppl):225–34.

Joura E.A, Leodolter S, Hernandez-Avila M, Wheeler C.M, Perez G, Koutsky LA, Garland S.M, Harper D.M, and et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 viruslike- particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet.2007.369:9574:1693-1702.

Petrosky E, Joseph A. Bocchini Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report (MMWR). 2015:64(11);300-304

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX , Franco E. Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. Jnl of National Cancer Institute.2004;.96;604-6015.

National and state vaccination coverage among adolescents aged 13-17 years--United States, Centers for Disease

Control and Prevention (CDC). Morb Mortal Wkly Rep. 2013 Aug 30;62(34):685-93.

SangyS, Miryousefi Ata F, Miryousefiata F. Study of Thymus and T- cell Development and TumorImmunology. Budapest International Research in Exact Sciences (BirEx) Journal

Volume 3, No 3, July 2021, Page: 162-170. DOI:

Szarewsk A.HPV Vaccination and Cervical Cancer. Cancer Prevention. Current Oncology Reports.2012; 14 : 559-567

Giuliano A.R. Palefsky J.M. Goldstone S, Moreira E.D. Penny M.E. Aranda C, Vardas E, Moi H, Jessen H. Hillman R. and et al. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. N Engl J Med 2011; 364:401-411

Reiter P.L, Brewer NT, Gottlieb S.L, McRee A.L.Smith J.S. How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen. Vaccine 2009:27:6840–6844.

Miryousefiata F, Sangy S. Assessing the Correct Understanding of Families about the Occurrence of Marital Cancer (Statistical Population: Denmark, Sweden and Iran), J. Med. Chem. Sci., 2021, 4(1) 60-74 DOI: 10.26655/JMCHEMSCI.2021.1.8 URL:


Article Metrics

Abstract view : 88 times
PDF - 38 times


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


Statcounter for Budapest International Research in Exact Sciences (BirEx Journal)